BP
ALLO icon

BBR Partners’s Allogene Therapeutics ALLO Stock Holding History

BBR Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.6K Hold
28,952
– – ﹤0.01% 249
2025
Q4 		$39.7K Hold
28,952
– – ﹤0.01% 265
2025
Q3 		$35.9K Hold
28,952
– – ﹤0.01% 268
2025
Q2 		$32.7K Hold
28,952
– – ﹤0.01% 235
2025
Q1 		$42.3K Hold
28,952
– – ﹤0.01% 240
2024
Q4 		$61.7K Hold
28,952
– – ﹤0.01% 243
2024
Q3 		$81.1K Hold
28,952
– – 0.01% 234
2024
Q2 		$67.5K Hold
28,952
– – 0.01% 212
2024
Q1 		$129K Hold
28,952
– – 0.01% 241
2023
Q4 		$92.9K Hold
28,952
– – 0.01% 184
2023
Q3 		$91.8K Hold
28,952
– – 0.01% 188
2023
Q2 		$144K Hold
28,952
– – 0.02% 151
2023
Q1 		$143K Hold
28,952
– – 0.02% 157
2022
Q4 		$182K Hold
28,952
– – 0.02% 165
2022
Q3 		$313K Hold
28,952
– – 0.04% 134
2022
Q2 		$330K Hold
28,952
– – 0.04% 165
2022
Q1 		$264K Sell
28,952
-35,053
-55% -$365K 0.02% 197
2021
Q4 		$955K Buy
64,005
+28,952
+83% +$511K 0.11% 83
2021
Q3 		$901K Sell
35,053
-3,955
-10% -$93.9K 0.07% 99
2021
Q2 		$1.02M Hold
39,008
– – 0.08% 94
2021
Q1 		$1.38M Buy
+39,008
New +$1.32M 0.11% 73

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BBR Partners's ALLO Position: Q1 2026 in Review

BBR Partners held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 28,952 shares worth $70.6K. The position accounts for ﹤0.01% of the portfolio, ranked #249.

BBR Partners first reported a position in ALLO in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.38M in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • BBR Partners held 28,952 shares of Allogene Therapeutics worth $70.6K as of Q1 2026.
  • BBR Partners left its Allogene Therapeutics share count unchanged in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of BBR Partners's portfolio in Q1 2026, its #249 holding.
  • BBR Partners first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • BBR Partners's Allogene Therapeutics position peaked at $1.38M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on BBR Partners's 13F filing for Q1 2026, filed 12 May 2026.